Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solut... Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. 詳細を表示
NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.24 | -11.6504854369 | 2.06 | 2.14 | 1.82 | 393178 | 1.94376853 | CS |
4 | -0.13 | -6.66666666667 | 1.95 | 2.24 | 1.75 | 316950 | 1.91798315 | CS |
12 | -0.21 | -10.3448275862 | 2.03 | 2.63 | 1.56 | 443648 | 1.98102833 | CS |
26 | -0.45 | -19.8237885463 | 2.27 | 3.12 | 1.56 | 445708 | 2.15283462 | CS |
52 | 0.9738 | 115.079177499 | 0.8462 | 3.12 | 0.7912 | 371095 | 1.91967891 | CS |
156 | -0.56 | -23.5294117647 | 2.38 | 3.12 | 0.45 | 277040 | 1.57694418 | CS |
260 | -0.81 | -30.7984790875 | 2.63 | 4.96 | 0.45 | 330284 | 2.05108368 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約